Gavin Giovannoni

List of Publications by Year
in descending order

367 papers	28,796 citations	10475 72 h-index	6540 158 g-index
430 all docs	430 docs citations	430 times ranked	23312 citing authors

#	Article	IF	Citations
1	Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ Open, 2024, 14, e083582.	2.1	1
2	Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open, 2024, 14, e086414.	2.1	0
3	Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2024, 11, .	6.8	0
4	Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Scientific Reports, 2023, 13, .	3.4	4
5	Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method. Therapeutic Advances in Neurological Disorders, 2023, 16, .	3.8	2
6	Is it ethical to use teriflunomide as an active comparator in phase 3 trials?. Multiple Sclerosis and Related Disorders, 2023, 78, 104911.	2.1	1
7	Safety and efficacy with alemtuzumab over 13â€‰years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study. Therapeutic Advances in Neurological Disorders, 2023, 16, .	3.8	3
8	Disease activity 4.5â€‰years after starting cladribine: experience in 264 patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2023, 16, .	3.8	2
9	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Multiple Sclerosis Journal, 2022, 28, 111-120.	3.3	18
10	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	5.8	131
11	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. Multiple Sclerosis and Related Disorders, 2022, 57, 103409.	2.1	3
12	Derisking CD20-therapies for long-term use. Multiple Sclerosis and Related Disorders, 2022, 57, 103418.	2.1	6
13	Side Effects That Occurred Early in People With Multiple Sclerosis During the First Year of Treatment With Cladribine Tablets: A Plain Language Summary. Neurodegenerative Disease Management, 2022, 12, 1-7.	2.3	2
14	Update on NHS Reset and Reform achievements in 2021. British Journal of Neuroscience Nursing, 2022, 18, S20-S24.	0.2	1
15	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103448.	2.1	20
16	Smouldering multiple sclerosis: the â€˜real MSâ€™. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642110667.	3.8	106
17	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	2.1	12
18	Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair. Multiple Sclerosis and Related Disorders, 2022, 58, 103539.	2.1	4

#	Article	IF	Citations
19	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. Lancet Regional Health - Europe, The, 2022, 15, 100321.	7.8	16
20	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2022, 207, 263-271.	2.7	14
21	Prevalence of disability improvement in relapsingâ€“remitting multiple sclerosis patients treated with cladribine tablets. European Journal of Neurology, 2022, 29, 2144-2147.	3.6	4
22	Implications of Low-Titer MOG Antibodies. Multiple Sclerosis and Related Disorders, 2022, 59, 103746.	2.1	11
23	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. JAMA Neurology, 2022, 79, 359.	9.3	36
24	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	3.3	20
25	Exercise training in multiple sclerosis. Lancet Neurology, The, 2022, 21, 313.	10.4	8
26	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	3.3	22
27	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. Multiple Sclerosis and Related Disorders, 2022, 61, 103757.	2.1	12
28	Extended dosing of monoclonal antibodies in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2001-2009.	3.3	21
29	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.3	15
30	How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?. Multiple Sclerosis and Related Disorders, 2022, 63, 103803.	2.1	1
31	Cladribine Tablets for Relapsingâ€“Remitting Multiple Sclerosis: A Clinicianâ€™s Review. Neurology and Therapy, 2022, 11, 571-595.	3.5	28
32	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	10.4	58
33	High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. Multiple Sclerosis and Related Disorders, 2022, 61, 103816.	2.1	0
34	Onset of multiple sclerosis is preventable â€“ time to act now!. Multiple Sclerosis and Related Disorders, 2022, 62, 103875.	2.1	1
35	Age-specific effects of childhood body mass index on multiple sclerosis risk. Journal of Neurology, 2022, 269, 5052-5060.	3.8	5
36	The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis. European Journal of Neurology, 2022, 29, 2754-2760.	3.6	6

#	Article	IF	Citations
37	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	3.8	7
38	Multiple sclerosis is one disease. Multiple Sclerosis and Related Disorders, 2022, 63, 103961.	2.1	5
39	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. BMJ Neurology Open, 2022, 4, e000240.	2.0	18
40	EBV as the â€œgluten of MSâ€•hypothesis provides a rationale for trialing antiviral therapies. Multiple Sclerosis and Related Disorders, 2022, 64, 104007.	2.1	0
41	MSProDiscussâ„¢ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression. Journal of Clinical Medicine, 2022, 11, 4401.	2.5	5
42	EBV and multiple sclerosis: Setting the research agenda. Multiple Sclerosis and Related Disorders, 2022, 67, 104158.	2.1	2
43	Towards a global view of multiple sclerosis genetics. Nature Reviews Neurology, 2022, 18, 613-623.	10.0	9
44	Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model. Multiple Sclerosis and Related Disorders, 2022, 68, 104222.	2.1	0
45	Social determinants of health in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 723-734.	10.0	41
46	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	3.3	17
47	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.3	5
48	Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. Multiple Sclerosis and Related Disorders, 2021, 47, 102624.	2.1	1
49	Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. Drugs, 2021, 81, 207-231.	11.1	100
50	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. International Journal of Epidemiology, 2021, 49, 2051-2057.	2.0	10
51	Is multiple sclerosis overdiagnosed?. Multiple Sclerosis and Related Disorders, 2021, 47, 102721.	2.1	2
52	Amyloidoma mimicking multiple sclerosis. Practical Neurology, 2021, 21, 344-345.	1.6	1
53	Air pollution and multiple sclerosis risk. Multiple Sclerosis and Related Disorders, 2021, 48, 102797.	2.1	3
54	Predicting disability worsening in relapsing and progressive multiple sclerosis. Current Opinion in Neurology, 2021, 34, 312-321.	3.7	10

#	Article	IF	Citations
55	B cell therapy and the use of RNA-based COVID-19 vaccines. Multiple Sclerosis and Related Disorders, 2021, 49, 102887.	2.1	5
56	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research, 2021, 23, e29558.	4.5	11
57	Improving estimation of Parkinsonâ€™s disease riskâ€”the enhanced PREDICT-PD algorithm. Npj Parkinson's Disease, 2021, 7, 33.	5.4	17
58	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102931.	2.1	2
59	Gene-Environment Interactions in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.8	37
60	Gender issues during the times of COVIDâ€19 pandemic. European Journal of Neurology, 2021, 28, e73-e77.	3.6	6
61	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110242.	1.1	4
62	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 53, 103155.	2.1	12
63	Can rheumatologists stop causing demyelinating disease?. Multiple Sclerosis and Related Disorders, 2021, 53, 103057.	2.1	4
64	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. Journal of Neuroimmunology, 2021, 357, 577627.	2.4	38
65	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5Âmg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. Advances in Therapy, 2021, 38, 4975-4985.	3.0	19
66	Evaluation of remote assessments for multiple sclerosis in an in-home setting. Multiple Sclerosis and Related Disorders, 2021, 54, 103125.	2.1	4
67	Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2021, 56, 103284.	2.1	1
68	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 295-302.	6.0	19
69	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 96, e376-e386.	1.1	64
70	Optimising classification of Parkinsonâ€™s disease based on motor, olfactory, neuropsychiatric and sleep features. Npj Parkinson's Disease, 2021, 7, 87.	5.4	5
71	Measuring treatment response to advance precision medicine for multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 2166-2173.	3.7	8
72	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110576.	3.8	6

#	Article	IF	Citations
73	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. BMJ Neurology Open, 2021, 3, e000192.	2.0	3
74	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. Multiple Sclerosis and Related Disorders, 2021, 56, 103426.	2.1	0
75	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.8	10
76	Predicting Multiple Sclerosis: Challenges and Opportunities. Frontiers in Neurology, 2021, 12, 761973.	2.5	9
77	Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Frontiers in Immunology, 2021, 12, 763433.	4.9	4
78	Inclusion criteria used in trials of people with progressive multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 279-283.	3.3	3
79	Epsteinâ€“Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends in Molecular Medicine, 2020, 26, 296-310.	7.1	188
80	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. Neurology and Therapy, 2020, 9, 335-358.	3.5	3
81	CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.8	14
82	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2020, 19, 988-997.	10.4	75
83	Distinguishing physiological versus pathological serum NfL levels in multiple sclerosis will require serial measurements. Multiple Sclerosis and Related Disorders, 2020, 46, 102477.	2.1	1
84	Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences, 2020, 417, 117079.	0.6	12
85	Parkinsonâ€™s disease determinants, prediction and geneâ€“environment interactions in the UK Biobank. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1046-1054.	6.0	68
86	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102572.	2.1	41
87	Regarding: Nicotinic acetylcholine receptors Î±7 and Î±9 modify tobacco smoke risk for multiple sclerosis. Multiple Sclerosis Journal, 2020, 27, 135245852096994.	3.3	0
88	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2020, 43, 102174.	2.1	64
89	Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. Multiple Sclerosis and Related Disorders, 2020, 43, 102209.	2.1	5
90	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 44, 102241.	2.1	28

#	Article	IF	Citations
91	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health, 2020, 20, 912.	3.0	101
92	Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.8	9
93	Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 42, 102259.	2.1	8
94	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurology, 2020, 77, 1132.	9.3	317
95	The impact of social capital on patients with multiple sclerosis. Acta Neurologica Scandinavica, 2020, 142, 58-65.	2.2	8
96	Systematic review and meta-analysis of the association between Epsteinâ€“Barr virus, multiple sclerosis and other risk factors. Multiple Sclerosis Journal, 2020, 26, 1281-1297.	3.3	62
97	The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2020, 39, 102073.	2.1	157
98	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 102024.	2.1	6
99	Protecting people with multiple sclerosis through vaccination. Practical Neurology, 2020, 20, 435.1-445.	1.6	43
100	Expert opinion on the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093501.	3.8	25
101	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology, 2020, 95, e1027-e1040.	1.1	29
102	Health-care disparities for people with multiple sclerosis. Lancet Neurology, The, 2020, 19, 207-208.	10.4	7
103	A Cell-Based Assay for the Detection of Neutralizing Antibodies Against Alemtuzumab. BioTechniques, 2020, 68, 185-190.	1.8	2
104	The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies. Frontiers in Immunology, 2020, 11, 124.	4.9	24
105	GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains. Scientific Reports, 2020, 10, 1860.	3.4	7
106	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.4	94
107	BMI and low vitamin D are causal factors for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.8	75
108	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. Annals of Neurology, 2020, 87, 599-608.	5.8	23

#	Article	IF	Citations
109	World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application. Multiple Sclerosis Journal, 2020, 26, 153-158.	3.3	5
110	Ageing and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101953.	2.1	1
111	Severe skin reactions associated with cladribine in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 43, 102140.	2.1	6
112	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 483-492.	6.0	27
113	Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Multiple Sclerosis and Related Disorders, 2020, 41, 102135.	2.1	44
114	Long-term safety and efficacy of daclizumab beta in relapsingâ€“remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. Journal of Neurology, 2020, 267, 2851-2864.	3.8	8
115	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. Neurology and Therapy, 2020, 9, 359-374.	3.5	31
116	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Safety, 2020, 43, 635-643.	3.2	24
117	Enzymatic degradation of <scp>RNA</scp> causes widespread protein aggregation in cell and tissue lysates. EMBO Reports, 2020, 21, e49585.	5.1	26
118	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.8	12
119	CLINICAL VIEWPOINT: Immunosuppression and COVID-19. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 8-9.	0.1	0
120	Dare we mention the C-word?. Multiple Sclerosis and Related Disorders, 2020, 43, 102340.	2.1	0
121	Remote testing of vitamin D levels across the UK MS populationâ€”A case control study. PLoS ONE, 2020, 15, e0241459.	2.5	3
122	Do we have equipoise when it comes to how we treat active multiple sclerosis?. Lancet Neurology, The, 2019, 18, 909-911.	10.4	3
123	Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641985498.	3.8	79
124	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	10.4	126
125	Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. Advances in Therapy, 2019, 36, 3238-3252.	3.0	21
126	Cerebrospinal fluid NCAM levels are modulated by diseaseâ€modifying therapies. Acta Neurologica Scandinavica, 2019, 139, 422-427.	2.2	6

#	Article	IF	Citations
127	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 168-174.	2.1	102
128	Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 19-25.	2.1	14
129	Screening performance of abbreviated versions of the UPSIT smell test. Journal of Neurology, 2019, 266, 1897-1906.	3.8	44
130	Survival: the ultimate long-term outcome in multiple sclerosis. Brain, 2019, 142, 1166-1167.	8.0	2
131	Chronic-relapsing varicella zoster meningitis â€“ Successfully treated with varicella vaccine. Journal of Infection, 2019, 79, 61-74.	3.4	0
132	Visibility and representation of women in multiple sclerosis research. Neurology, 2019, 92, 713-719.	1.1	14
133	Social capital: Implications for neurology. Brain and Behavior, 2019, 9, e01169.	2.3	8
134	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders, 2019, 27, 247-253.	2.1	11
135	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Multiple Sclerosis and Related Disorders, 2019, 29, 157-167.	2.1	99
136	UK consensus on pregnancy in multiple sclerosis: â€˜Association of British Neurologistsâ€™ guidelines. Practical Neurology, 2019, 19, 106-114.	1.6	124
137	Is the â€˜MS establishmentâ€™ biased; the case for addressing gender inequality in the field of MS?. Multiple Sclerosis and Related Disorders, 2019, 28, 153-154.	2.1	4
138	Should our treatment target in MS include the intrathecal plasma cell response?. Multiple Sclerosis and Related Disorders, 2019, 27, A1-A2.	2.1	1
139	The Multiple Sclerosis Care Unit. Multiple Sclerosis Journal, 2019, 25, 627-636.	3.3	98
140	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	3.3	63
141	The unintended consequences of NICE. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 247-248.	6.0	0
142	Learning ability correlates with brain atrophy and disability progression in RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 38-43.	6.0	18
143	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Multiple Sclerosis Journal, 2019, 25, 819-827.	3.3	52
144	The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. Journal of Neurology, 2018, 265, 285-290.	3.8	13

#	Article	IF	Citations
145	No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. Journal of Neurology, 2018, 265, 1089-1095.	3.8	78
146	Complexity of MS management in the current treatment era. Neurology, 2018, 90, 761-762.	1.1	5
147	Are the high-costs of MS disease-modifying therapies justified?. Multiple Sclerosis and Related Disorders, 2018, 20, A3-A5.	2.1	2
148	Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Current Opinion in Neurology, 2018, 31, 233-243.	3.7	132
149	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsingâ€“remitting multiple sclerosis: the CLARITY Extension study. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775336.	3.8	47
150	Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology, 2018, 154, 253-260.	4.4	33
151	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.1	33
152	Human Endogenous Retroviruses in Neurological Diseases. Trends in Molecular Medicine, 2018, 24, 379-394.	7.1	222
153	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	12.1	726
154	Corrigendum to â€˜Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Clinical Therapeutics, 2018, 40, 812.	2.3	0
155	Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. Journal of Neurology, 2018, 265, 1199-1209.	3.8	121
156	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Multiple Sclerosis Journal, 2018, 24, 222-226.	3.3	50
157	Psychiatric disorders in children with demyelinating diseases of the central nervous system. Multiple Sclerosis Journal, 2018, 24, 1243-1250.	3.3	21
158	A brief history of NEDA. Multiple Sclerosis and Related Disorders, 2018, 20, 228-230.	2.1	40
159	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891.	3.3	2
160	Vitamin D supplementation. Practical Neurology, 2018, 18, 35-42.	1.6	45
161	Safety and efficacy of cladribine tablets in patients with relapsingâ€“remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal, 2018, 24, 1594-1604.	3.3	249
162	Circulating lymphocyte levels and relationship with infection status in patients with relapsingâ€“remitting multiple sclerosis treated with daclizumab beta. Multiple Sclerosis Journal, 2018, 24, 1725-1736.	3.3	3

#	Article	IF	Citations
163	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2018, 19, 153-160.	2.1	112
164	Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier. Neurology and Therapy, 2018, 7, 179-187.	3.5	24
165	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. Multiple Sclerosis Journal, 2018, 24, 1862-1870.	3.3	49
166	e-Health and multiple sclerosis: An update. Multiple Sclerosis Journal, 2018, 24, 1657-1664.	3.3	71
167	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	30.1	254
168	Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. Brain, 2018, 141, 2834-2847.	8.0	43
169	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Annals of Neurology, 2018, 84, 527-536.	5.8	43
170	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	2.1	44
171	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. Journal of Neurology, 2018, 265, 1795-1802.	3.8	7
172	Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Multiple Sclerosis and Related Disorders, 2018, 24, 20-27.	2.1	16
173	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders, 2018, 24, 123-128.	2.1	26
174	Women on multiple sclerosis clinical trial steering committees. Annals of Neurology, 2018, 84, 329-330.	5.8	11
175	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders, 2018, 25, 197-199.	2.1	15
176	Is cognitive impairment in multiple sclerosis reversible?. Multiple Sclerosis and Related Disorders, 2018, 23, A1.	2.1	0
177	Peripheral blood neurofilament light chain levels: the neurologistâ€™s C-reactive protein?. Brain, 2018, 141, 2235-2237.	8.0	29
178	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731878376.	1.1	7
179	Cladribine: mechanisms and mysteries in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1266-1271.	6.0	62
180	No Evident Disease Activityâ€"More Than a Risky Ambition?. JAMA Neurology, 2018, 75, 781.	9.3	9

#	Article	IF	Citations
181	Increased expression of colonyâ€stimulating factorâ€1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. Glia, 2018, 66, 2108-2125.	5.3	36
182	Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial. Journal of Neurotrauma, 2018, 35, 1918-1928.	3.6	26
183	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis and Related Disorders, 2017, 12, 70-78.	2.1	97
184	Should we rebrand multiple sclerosis a dementia?. Multiple Sclerosis and Related Disorders, 2017, 12, 79-81.	2.1	10
185	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology, 2017, 88, 826-831.	1.1	175
186	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Movement Disorders, 2017, 32, 219-226.	4.3	62
187	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine, 2017, 16, 41-50.	6.0	230
188	Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. Multiple Sclerosis and Related Disorders, 2017, 14, 46-50.	2.1	21
189	How to start a blog. Practical Neurology, 2017, 17, 224-228.	1.6	2
190	The neurodegenerative prodrome in multiple sclerosis. Lancet Neurology, The, 2017, 16, 413-414.	10.4	30
191	Subtle motor disturbances in PREDICT-PD participants. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 212-217.	6.0	19
192	Can we afford not to prevent MS-related disability?. Multiple Sclerosis Journal, 2017, 23, 1048-1049.	3.3	6
193	The â€˜Field Hypothesisâ€™: rebound activity after stopping disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2017, 15, A1-A2.	2.1	14
194	Science is 1% inspiration and 99% biomarkers. Multiple Sclerosis Journal, 2017, 23, 1442-1452.	3.3	20
195	Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurology, 2017, 74, 961.	9.3	205
196	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Multiple Sclerosis Journal, 2017, 23, 1736-1747.	3.3	19
197	â€œNo evident disease activityâ€: The use of combined assessments in the management of patients with multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1179-1187.	3.3	134
198	Depletion of <scp>CD</scp>52â€positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immuneâ€tolerance promoting <scp>CD</scp>8 Tâ€cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. Immunology, 2017, 150, 444-455.	4.4	44

#	Article	IF	Citations
199	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	30.1	1,424
200	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	30.1	1,402
201	Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. Multiple Sclerosis and Related Disorders, 2017, 18, 181-183.	2.1	33
202	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	194
203	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	238
204	Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. Annals of Clinical and Translational Neurology, 2017, 4, 506-511.	3.7	16
205	Tackling comorbidity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 144-145.	2.1	7
206	Disease modification in advanced MS: Focus on upper limb function. Multiple Sclerosis Journal, 2017, 23, 1956-1957.	3.3	9
207	Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clinical Therapeutics, 2017, 39, 1671-1679.	2.3	28
208	Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics, 2017, 14, 874-887.	4.7	100
209	Personalized Medicine in Multiple Sclerosis. Neurodegenerative Disease Management, 2017, 7, 13-17.	2.3	25
210	Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Multiple Sclerosis and Related Disorders, 2017, 17, 172-176.	2.1	9
211	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 32-40.	2.1	10
212	Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1Î². Journal of Neuroinflammation, 2017, 14, 131.	7.4	41
213	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1367-1376.	3.3	29
214	Epstein-Barrâ€“negative MS: a true phenomenon?. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e318.	6.8	34
215	A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technology Assessment, 2017, 21, 1-50.	2.9	20
216	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	6.0	97

#	Article	IF	Citations
217	A Risk Score for Predicting Multiple Sclerosis. PLoS ONE, 2016, 11, e0164992.	2.5	13
218	Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S5-S48.	2.1	303
219	Gavin Giovannoni On Why Time Matters in Multiple Sclerosis. Neurodegenerative Disease Management, 2016, 6, 77-79.	2.3	2
220	Why do you have to be lucky to get the MS treatment you deserve?. Multiple Sclerosis and Related Disorders, 2016, 8, A3-A4.	2.1	2
221	Time and brain health both matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S1-S3.	2.1	6
222	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.1	59
223	Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurology, 2016, 16, 389-393.	1.6	41
224	The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Multiple Sclerosis Journal, 2016, 22, 34-46.	3.3	50
225	Multiple Sclerosis and Demyelinating Diseases. , 2016, , 475-511.		2
226	A practical review of the neuropathology and neuroimaging of multiple sclerosis. Practical Neurology, 2016, 16, 279-287.	1.6	31
227	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon Î²-1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	31
228	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurology, 2016, 16, 117.	1.8	42
229	How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 127-133.	2.1	6
230	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Multiple Sclerosis and Related Disorders, 2016, 9, 36-46.	2.1	51
231	Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. JAMA Neurology, 2016, 73, 954.	9.3	17
232	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 259-269.	10.4	169
233	The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 49-53.	2.1	48
234	IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. Practical Neurology, 2016, 16, 235-239.	1.6	9

#	Article	IF	Citations
235	How long is the presymptomatic phase of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2016, 7, 12-13.	2.1	9
236	Cytokine profiles show heterogeneity of interferon-Î² response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202.	6.8	35
237	Gender identity disorders and multiple sclerosis risk: A national record-linkage study. Multiple Sclerosis Journal, 2016, 22, 1759-1762.	3.3	29
238	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsingâ€“Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurology and Therapy, 2016, 5, 45-57.	3.5	34
239	Optimizing treatment success in multiple sclerosis. Journal of Neurology, 2016, 263, 1053-1065.	3.8	159
240	Webâ€based assessment of Parkinson's prodromal markers identifies GBA variants. Movement Disorders, 2015, 30, 1002-1003.	4.3	6
241	Systematic review and metaâ€analysis of salivary protein concentration in <scp>P</scp>arkinson's disease. Movement Disorders, 2015, 30, 1971-1972.	4.3	2
242	Timing is everything in the treatment of multiple sclerosis. BMJ Case Reports, 2015, 2015, bcr2014208960.	0.5	1
243	Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2015, 4, 329-333.	2.1	286
244	Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities. BMC Health Services Research, 2015, 15, 105.	2.2	29
245	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	112
246	Evaluating more naturalistic outcome measures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e162.	6.8	57
247	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. Multiple Sclerosis and Related Disorders, 2015, 4, 83-84.	2.1	8
248	Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. Biosensors and Bioelectronics, 2015, 68, 660-667.	10.4	75
249	Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. Multiple Sclerosis and Related Disorders, 2015, 4, 88-91.	2.1	4
250	HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 9-12.	6.0	79
251	The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2015, 4, 3-5.	2.1	14
252	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2015, 4, 202-218.	2.1	90

#	Article	IF	Citations
253	Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 565-573.	6.0	94
254	Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Journal of NeuroImmune Pharmacology, 2015, 10, 281-292.	4.0	43
255	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	1.6	171
256	Neurofilament light chain. Neurology, 2015, 84, 2247-2257.	1.1	439
257	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology, 2015, 84, 1639-1643.	1.1	158
258	The role of infections in BehÃ§et disease and neuro-BehÃ§et syndrome. Autoimmunity Reviews, 2015, 14, 609-615.	5.9	19
259	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as aÂpotential marker of disease severity. Parkinsonism and Related Disorders, 2015, 21, 1251-1255.	2.2	46
260	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosisâ€“related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics, 2015, 37, 2543-2551.	2.3	9
261	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsingâ€“remitting multiple sclerosis (RRMS). Multiple Sclerosis Journal, 2015, 21, 57-66.	3.3	56
262	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 273-279.	6.0	153
263	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of MS Care, 2015, 17, 236-243.	1.0	50
264	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. PLoS ONE, 2014, 9, e96260.	2.5	53
265	The Refinement of Genetic Predictors of Multiple Sclerosis. PLoS ONE, 2014, 9, e96578.	2.5	16
266	Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurology, 2014, 14, 237.	1.8	11
267	Disease-activity-free status in patients with relapsingâ€“remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Multiple Sclerosis Journal, 2014, 20, 464-470.	3.3	26
268	Assessing treatment response to interferon-Î². Neurology, 2014, 82, 248-254.	1.1	61
269	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 31-37.	6.0	93
270	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Multiple Sclerosis and Related Disorders, 2014, 3, 705-711.	2.1	34

#	Article	IF	Citations
271	No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsingâ€“Remitting Multiple Sclerosis. Advances in Therapy, 2014, 31, 1134-1154.	3.0	84
272	Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 274-278.	6.0	52
273	Developing Biomarkers for MS. Current Topics in Behavioral Neurosciences, 2014, 26, 179-194.	0.0	6
274	Alcohol Misuse Disorders and Multiple Sclerosis Risk. JAMA Neurology, 2014, 71, 1188.	9.3	19
275	Multiple sclerosis therapy and Epsteinâ€“Barr virus antibody titres. Multiple Sclerosis and Related Disorders, 2014, 3, 372-374.	2.1	15
276	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. Journal of Neurology, 2014, 261, 316-323.	3.8	19
277	Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain, 2014, 137, 92-108.	8.0	38
278	MSer â€“ A new, neutral descriptor for someone with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 31-33.	2.1	5
279	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Clinical Therapeutics, 2014, 36, 1958-1971.	2.3	36
280	Natalizumab to fingolimod washout in patients at risk of PML. Neurology, 2014, 82, 1196-1197.	1.1	17
281	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. Multiple Sclerosis Journal, 2014, 20, 1182-1188.	3.3	26
282	Simvastatin in patients with progressive multiple sclerosis. Lancet, The, 2014, 384, 952.	12.1	2
283	Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1355-1362.	3.3	33
284	Cerebrospinal fluid analysis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 681-702.	0.3	32
285	Control of spasticity in a multiple sclerosis model using central nervous systemâ€excluded CB ₁ cannabinoid receptor agonists. FASEB Journal, 2014, 28, 117-130.	0.5	32
286	CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age. Multiple Sclerosis and Related Disorders, 2014, 3, 143-146.	2.1	11
287	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurology, The, 2014, 13, 472-481.	10.4	84
288	Epsteinâ€“Barr virus, latitude and multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 362-365.	3.3	34

#	Article	IF	Citations
289	Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE). Inflammation Research, 2013, 62, 659-667.	4.0	8
290	Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. Journal of Neurology, 2013, 260, 2505-2510.	3.8	35
291	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology, 2013, 260, 1136-1146.	3.8	49
292	Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. Practical Neurology, 2013, 13, 70-79.	1.6	25
293	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 162-166.	3.3	142
294	Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathologica Communications, 2013, 1, 84.	5.4	26
295	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 381, 2167-2175.	12.1	270
296	Editors' welcome and a working definition for a multiple sclerosis cure. Multiple Sclerosis and Related Disorders, 2013, 2, 65-67.	2.1	62
297	ECTRIMS 2012: Treatment highlights. Multiple Sclerosis and Related Disorders, 2013, 2, 68-72.	2.1	1
298	Epsteinâ€“Barr virus and multiple sclerosis: association or causation?. Expert Review of Neurotherapeutics, 2013, 13, 287-297.	2.8	46
299	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsingâ€“remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology, 2013, 260, 2297-2305.	3.8	67
300	Neural cell adhesion molecules in brain plasticity and disease. Multiple Sclerosis and Related Disorders, 2013, 2, 13-20.	2.1	35
301	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS â€“ Neurofilament as a Surrogate of Disease Progression. PLoS ONE, 2013, 8, e70019.	2.5	50
302	Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2013, 8, e76907.	2.5	44
303	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	395
304	Neuroprotection in a Novel Mouse Model of Multiple Sclerosis. PLoS ONE, 2013, 8, e79188.	2.5	32
305	Individualizing treatment goals and interventions for people with MS. Current Opinion in Neurology, 2012, 25, S20-S27.	3.7	15
306	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 298-304.	6.0	175

#	Article	IF	Citations
307	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	12.1	1,062
308	Metaâ€analysis of early nonmotor features and risk factors for Parkinson disease. Annals of Neurology, 2012, 72, 893-901.	5.8	626
309	Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical Drug Investigation, 2012, 32, 15-27.	2.2	11
310	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1098-1107.	30.1	1,529
311	The REFLEX study: a missed opportunity?. Lancet Neurology, The, 2012, 11, 22-24.	10.4	3
312	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. Multiple Sclerosis and Related Disorders, 2012, 1, 9-14.	2.1	39
313	Cladribine tablets for relapsingâ€“remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders, 2012, 1, 49-54.	2.1	29
314	Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Multiple Sclerosis and Related Disorders, 2012, 1, 29-38.	2.1	63
315	The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2012, 1, 64-75.	2.1	28
316	Emerging disease modifying treatmentsâ€”A therapeutics update from ECTRIMS/ACTRIMS, Amsterdam, 2011. Multiple Sclerosis and Related Disorders, 2012, 1, 56-58.	2.1	0
317	Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon. CNS and Neurological Disorders - Drug Targets, 2012, 11, 610-623.	1.6	30
318	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course. International Journal of MS Care, 2012, 14, 105-114.	1.0	19
319	Promising Emerging Therapies for Multiple Sclerosis. Neurologic Clinics, 2011, 29, 435-448.	1.9	8
320	Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Multiple Sclerosis Journal, 2011, 17, 939-948.	3.3	53
321	Smoking and Multiple Sclerosis: An Updated Meta-Analysis. PLoS ONE, 2011, 6, e16149.	2.5	228
322	More to come: Humoral immune responses in MS. Journal of Neuroimmunology, 2011, 240-241, 13-21.	2.4	7
323	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology, The, 2011, 10, 329-337.	10.4	207
324	Fingolimod modulates microglial activation to augment markers of remyelination. Journal of Neuroinflammation, 2011, 8, 76.	7.4	128

#	Article	IF	Citations
325	Therapies for multiple sclerosis: considerations in the pediatric patient. Nature Reviews Neurology, 2011, 7, 109-122.	10.0	43
326	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurology, The, 2010, 9, 727-739.	10.4	467
327	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	91
328	Neural cell adhesion molecule â€" Description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. Journal of Neuroimmunology, 2010, 225, 118-122.	2.4	30
329	Multiple sclerosis: a practical overview for clinicians. British Medical Bulletin, 2010, 95, 79-104.	6.9	80
330	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 416-426.	30.1	827
331	Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis. Journal of Interferon and Cytokine Research, 2010, 30, 715-726.	1.3	15
332	An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. PLoS ONE, 2010, 5, e12496.	2.5	265
333	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurology, The, 2009, 8, 254-260.	10.4	438
334	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	3.8	201
335	Recent developments in oral medications for the treatment of multiple sclerosis. Future Neurology, 2009, 5, 167-172.	0.5	0
336	Antineuronal antibodies in Parkinson's disease. Movement Disorders, 2008, 23, 958-963.	4.3	17
337	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. Journal of Neuroimmunology, 2008, 193, 120-129.	2.4	91
338	Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNÎ² in multiple sclerosis patients. Journal of Immunological Methods, 2008, 336, 113-118.	1.4	57
339	The implications of immunogenicity for protein-based multiple sclerosis therapies. Journal of the Neurological Sciences, 2008, 275, 7-17.	0.6	54
340	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomarkers in Medicine, 2007, 1, 111-119.	1.4	8
341	Multiple sclerosis: the environment and causation. Current Opinion in Neurology, 2007, 20, 261-268.	3.7	144
342	Immunogenicity and tolerability of an investigational formulation of interferon-Î²1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics, 2007, 29, 1128-1145.	2.3	38

#	Article	IF	Citations
343	The RebifÂ® New Formulation Story. Drugs in R and D, 2007, 8, 335-348.	2.2	32
344	Antineuronal antibody status and phenotype analysis in Tourette's syndrome. Movement Disorders, 2007, 22, 1424-1429.	4.3	31
345	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nature Medicine, 2007, 13, 492-497.	30.1	334
346	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 899-910.	30.1	2,982
347	Multiple Sclerosis Cerebrospinal Fluid Biomarkers. Disease Markers, 2006, 22, 187-196.	1.4	51
348	Infectious causes of multiple sclerosis. Lancet Neurology, The, 2006, 5, 887-894.	10.4	165
349	The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders. Journal of Neuroimmunology, 2006, 180, 29-32.	2.4	5
350	Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. Journal of Neuroimmunology, 2005, 165, 41-52.	2.4	70
351	Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis. Archives of Neurology, 2005, 62, 865-70.	4.5	498
352	Optimising MS disease-modifying therapies: antibodies in perspective. Journal of Neurology, 2004, 251, v30-v35.	3.8	3
353	Management of Secondary-Progressive Multiple Sclerosis. CNS Drugs, 2004, 18, 653-669.	6.2	22
354	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 2003, 126, 2191-2202.	8.0	333
355	The clinical significance of an intrathecal monoclonal immunoglobulin band. Neurology, 2003, 60, 1163-1166.	1.1	73
356	Strategies to treat and prevent the development of neutralizing anti-interferon-Î² antibodies. Neurology, 2003, 61, S13-7.	1.1	23
357	Multiple sclerosis and its pathophysiology. , 2002, , 1606-1619.		4
358	Postâ€streptococcal autoimmune dystonia with isolated bilateral striatal necrosis. Developmental Medicine and Child Neurology, 2002, 44, 485-489.	2.7	55
359	Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism. Journal of Neurology, 2001, 248, 707-707.	3.8	2
360	Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Annals of Neurology, 2001, 50, 588-595.	5.8	191

#	Article	IF	Citations
361	Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. Annals of Neurology, 2000, 47, 684-685.	5.8	10
362	The bradykinesia akinesia incoordination test (BRAIN TESTï¿½), an objective and user-friendly means to evaluate patients with Parkinsonism. Movement Disorders, 2000, 15, 641-647.	4.3	51
363	Increased Urinary Neopterin Excretion in Vaccinated Adults. Pteridines, 1996, 7, 82-86.	0.5	1
364	Cladribine to treat multiple sclerosis. , 0, , 358-369.		0
365	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	2.5	21
366	Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care. Advances in Therapy, 0, , .	3.0	0
367	Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals. Neurology and Therapy, 0, , .	3.5	0